mRNAワクチンと治療薬市場レポート：2022-2032

mRNA Vaccines & Therapeutics Market Report 2022-2032

レポート詳細 mRNAワクチンと治療薬市場レポート 2022-2032 :本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2022年8月30日	GBP4,500 部署ライセンスライセンス・価格情報注文方法はこちら	411	406	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

レポート詳細

mRNAワクチンと治療薬市場レポート 2022-2032:本レポートは、新たな収益の柱を目指すリーディングカンパニーが、業界とその背景にあるダイナミクスをより深く理解する上で、非常に有益なものとなるでしょう。また、異業種への進出や新地域での既存事業の拡大を目指す企業にとっても有用なレポートです。

CDMOは新たに商業化されたmRNAの市場でチャンスをつかむ
COVID-19へのmRNA技術の応用が成功したことで、バイオ医薬品会社は他の疾患に対するこの技術の機会をさらに探ろうと再活性化しています。mRNAとその送達プラットフォームに焦点を当てた治療用mRNAプログラムが大幅に増加しており、mRNAの細胞内への送達が大きな課題となっています。開発・製造受託機関（CDMO）も、この需要の急増に対応するため、生産能力の増強に迫られています。既存のCDMOの多くは、ワクチン開発のためのGMP基準に適合する製造能力とプロセスの開発およびアップグレードを通じて、巨額の資本投資を行っています。これらの企業は、mRNAの製造技術を強化するために、戦略的パートナーシップや買収を進めています。例えば、韓国のサムスン・バイオロジクスは2021年5月、モデナのCOVID-19 mRNAワクチンの無菌充填仕上げと包装・表示に関する契約をモデナと締結しています。2021年8月、Samsung Biologicsは、グローバル規模で顧客をサポートするための米国での研究開発センターの設立、多様なアプリケーションをサポートするためのプラットフォームの拡張など、3つの分野での計画を発表しました。

マーケットリサーチレポートを購入する前に、どのような質問をすべきでしょうか？
- mRNAワクチンと治療薬市場はどのように進化しているのか？
- mRNAワクチンと治療薬市場の推進要因と抑制要因は何ですか？
- 各mRNAワクチンと治療薬サブマーケットセグメントは予測期間中にどのように成長し、2032年にこれらのサブマーケットが占める収益はどの程度になるのでしょうか？
- 2022年から2032年にかけて、各mRNAワクチンと治療薬サブマーケットの市場シェアはどのように推移するのでしょうか？
- 2022年から2032年にかけて、市場全体の主な牽引役となるのは何でしょうか？
- 主要なmRNAワクチンと治療薬市場はマクロ経済力学に概ね追随するのか、それとも個々の国内市場が他を凌駕するのか？
- 2032年までに各国市場のシェアはどのように変化し、どの地域が2032年の市場をリードするのでしょうか？
- 主要プレイヤーは誰か、また予測期間中の見通しは？
- これらの主要企業のmRNAワクチンと治療薬プロジェクトはどのようなものですか？
- 2022年から2032年の間に、業界はどのように進化していくのでしょうか？現在および今後10年間に実施されるmRNAワクチンと治療薬プロジェクトにはどのような意味があるのでしょうか？
- mRNAワクチンと治療薬市場をさらに拡大するために、製品の商業化の必要性は高まっていますか？
- mRNAワクチンと治療薬市場はどこへ向かい、どのようにすれば市場の最前線に立つことができるのでしょうか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望は何か？

mRNAワクチンと治療薬市場に現在、そして今後10年間、どのような影響を与えるかを知る必要があります。
- 411ページにわたる本レポートでは、164の表と242のグラフを独占的に提供します。
- このレポートでは、業界における主要な収益性の高い分野をハイライトしているため、今すぐターゲットを絞ることができます。
- 世界、地域、国別の売上高と成長率を詳細に分析しています。
- 競合他社が成功した主要なトレンド、変化、収益予測をハイライトしています。

このレポートは、mRNAワクチンと治療薬市場が今後10年間にどのように発展するか、またCOVID-19の景気後退と回復の変動に合わせて、今日あなたにお伝えします。この市場は、過去10年間のどの時点よりも、今がより重要なのです。

レポートでは、COVID-19のバリエーションや経済データなど、お客様の市場に特化した独自の情報をお届けしています。

2032年までの予測やその他の分析により、商業的な展望が見えてくる
- 2032年までの収益予測に加え、直近の実績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望や展開など、独自の分析もご覧いただけます。
- 定性的分析（市場力学、促進要因、機会、阻害要因、課題など）、コスト構造、mRNAワクチンおよび治療薬の最近の開発による上昇の影響についてご覧いただけます。

本レポートでは、COVID-19が業界と貴社にどのような影響を与えるかについて、データ分析と貴重な洞察を掲載しています。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じています。

報告書の対象セグメント

mRNAワクチンと治療薬市場：タイプ別
- mRNA予防ワクチン
- 治療用ワクチン
- mRNA治療薬

mRNAワクチンと治療薬市場：ベクター別
- 自己増幅型mRNA
- 非増幅型mRNA

mRNAワクチンと治療薬市場： ベクター提供プラットフォーム別
・ネイキッドmRNA
・細胞特異性
・キャリア媒体
- ウイルス性
- 非ウイルス性（ポリマーベースベクター、脂質ナノ粒子、ペプチドベースベクター）

mRNAワクチンと治療薬市場：投与経路別
- 筋肉内
- 静脈内
- 皮内投与
- 皮下投与
- 頭蓋内

mRNAワクチンと治療薬市場：用途別
- 細胞治療
- タンパク質代替療法
- 遺伝子編集
- がん免疫療法
- 感染症(COVID-19を含む)

mRNAワクチンと治療薬市場：エンドユーザー別
- 病院・クリニック
- 研究機関

世界市場全体およびセグメントの収益予測に加え、4地域および20の主要国市場の収益予測も掲載しています。

北米
- 米国
- カナダ

欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他の欧州

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- その他のラテンアメリカ地域

MEA
- サウジアラビア
- UAE
- トルコ
- その他のMEA地域

mRNAワクチンと治療薬市場レポート2022-2032の主要企業のプロファイルと、これらの企業のこのセグメントに焦点を当てたいくつかの企業についても記載しています。

主要企業と市場成長の可能性
・ AstraZeneca PLC
・ Moderna
・ CureVac N.V.
・ BioNTech SE
・ Pfizer Inc.,
・ GSK PLC
・ Arcturus Therapeutics Holding Inc.
・ Translate Bio (now a Sanofi Company)
・ Sanofi
・ eTheRNA
・ Stemirna Therapeutics
・ Cartesian Therapeutics
・ Ethris

mRNAワクチンと治療薬市場の世界全体収益、2022年から2032年まで（金額ベース）は、2022年に643億3800万米ドルを突破すると弊社は試算しています。また、2032年までの間に大幅な売上増が予測されます。本調査では、最も大きな可能性を秘めた組織を特定しました。彼らの能力、進歩、商業的展望を発見することで、一歩先を行くことができます。

mRNAワクチンと治療薬市場、2022年から2032年までのレポートはどのように役立つのでしょうか？
410ページを超えるレポートでは、要約すると以下のような知識を得ることができます。

- mRNAワクチンと治療薬市場の2032年までの収益予測、サービス、企業規模、薬剤タイプ、治療分野の各予測を世界および地域レベルで掲載 - 業界の展望を見出し、投資と収益に最も有利な場所を見つけることが可能です。

- 4地域と22主要国市場の2032年までの収益予測 - mRNAワクチンと治療薬市場、2022年から2032年までの北米、欧州、アジア太平洋、ラテンアメリカ、MEAの市場予測をご覧いただけます。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要経済圏の市場も予測されています。

- mRNAワクチンと治療薬市場に関与する主要企業13社の企業プロファイルを含む、既存企業および市場参入を目指す企業の展望（2022年から2032年まで）。

他にはない情報
私たちの新しいレポートがあれば、知識の遅れを取り戻し、チャンスを逃す可能性が低くなります。私たちの研究が貴社の研究、分析、意思決定にどのように役立つかをご覧ください。Visiongainの研究は、mRNAワクチンと治療薬市場、2022年から2032年、市場の主要企業の商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。

ページTOPに戻る

1.レポートの概要
1.1 研究の目的
1.2 mRNAワクチンと治療薬市場の紹介
1.3 本レポートの特徴
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問には以下が含まれます。
1.6 本レポートは誰のためのものなのか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ)
1.9 関連するVisiongainのレポート
1.10 Visiongainについて

2 エグゼクティブサマリー

3 市場の概要
3.1 主要な調査結果
3.2 マーケットダイナミクス
3.2.1 市場の推進要因
3.2.1.1 COVID-19ワクチン成功後のmRNAの多様なアプリケーションの増加
3.2.1.2 市場成長を促進する大規模な研究資金調達
3.2.1.3 市場成長を促進する技術的進歩
3.2.2 市場の抑制要因
3.2.2.1 スケーラビリティと費用対効果が依然として大きなボトルネックに
3.2.3 市場機会
3.2.3.1 mRNAがんワクチン
3.2.3.2 アナリティクス、機械学習、クラウドデータウェアハウス
3.3 COVID-19 インパクト分析
3.4 ポーターのファイブフォース分析
3.4.1 供給者のバーゲニングパワー
3.4.2 バイヤーのバーゲニングパワー
3.4.3 競争相手との競合
3.4.4 代替品の脅威
3.4.5 新規参入の脅威
3.5 PEST分析
3.5.1 政治的要因
3.5.2 経済的要因
3.5.3 社会的要因
3.5.4 技術的要因

4 世界のmRNAワクチンと治療薬市場：タイプ別
4.1 主な調査結果
4.2 タイプ別成長展望
4.3 mRNAワクチンと治療薬の世界市場規模予測・予測（タイプ別）
4.4 予防用ワクチン
4.4.1 地域別市場規模、2022-2032年 (US$ Mn)
4.4.2 地域別市場シェア、2022-2032年(%)
4.5 治療用ワクチン市場
4.5.1 治療用ワクチンの地域別市場予測、2022-2032年 (US＄ Mn)
4.5.2 治療用ワクチンの地域別市場予測、2022-2032年(%)
4.6 mRNAセラピューティックの市場予測
4.6.1 mRNA治療薬の地域別市場予測 2022-2032 (US$ Mn)
4.6.2 mRNA治療薬の地域別市場予測（2022-2032年）(%)

5 mRNAワクチンと治療薬市場分析：用途別
5.1 主な調査結果
5.2 用途別成長展望
5.3 mRNAワクチンとセラピューティック世界市場規模予測・用途別予測
5.4 mRNAワクチンと治療薬のアプリケーション別市場シェア（2022年＆2032年）
5.5 細胞治療
5.5.1 細胞療法の地域別市場予測（2022年～2032年）（US$ Mn）
5.5.2 細胞療法の地域別市場シェア、2022年～2032年 (%)
5.6 遺伝子編集
5.6.1 遺伝子編集の地域別市場予測, 2022-2032 (US$ Mn)
5.6.2 遺伝子編集の地域別市場シェア、2022-2032年(%)
5.7 タンパク質置換療法
5.7.1 タンパク質置換療法の地域別市場予測、2022年～2032年（US$ Mn)
5.7.2 タンパク質置換療法の地域別市場シェア、2022-2032年(%)
5.8 がん免疫療法
5.8.1 がん免疫療法の地域別市場予測、2022-2032年 (US$ Mn)
5.8.2 がん免疫療法の地域別市場シェア、2022-2032年（%)
5.9 感染症
5.9.1 感染症の地域別市場予測, 2022-2032 (US$ Mn)
5.9.2 mRNA感染症アプリケーションの地域別市場シェア、2022-2032年(%)

6 mRNAワクチンと治療薬市場：ベクタープラットフォーム別
6.1 主な調査結果
6.2 ベクタープラットフォームセグメントの成長展望
6.3 mRNAワクチン＆セラピューティック世界市場規模予測・ベクタープラットフォーム別予測
6.4 mRNAワクチン＆治療薬の世界市場ベクタープラットフォーム別シェア（2022年＆2032年）
6.5 自己増幅型mRNA
6.5.1 自己増幅型mRNAの地域別市場予測、2022年～2032年 (US$ Mn)
6.5.2 自己増幅型mRNAの地域別市場シェア、2022年～2032年(%)
6.6 非増幅型（従来型）mRNA
6.6.1 非増幅型mRNAの地域別市場予測、2022年～2032年 (US$ Mn)
6.6.2 非補完性mRNAの地域別市場シェア、2022年〜2032年(%)

7 世界のmRNAワクチンと治療薬市場：配信形態別
7.1 主な調査結果
7.2 デリバリー・プラットフォーム・セグメントの成長展望
7.3 mRNAワクチンと治療薬の世界市場規模予測・予測、デリバリープラットフォーム別（2022年＆2032年）
7.4 ネイキッドmRNAデリバリー
7.4.1 ネイキッドデリバリープラットフォームの地域別予測、2022年～2032年 (US$ Mn)
7.4.2 ネイキッドデリバリープラットフォームの地域別市場シェア、2022年～2032年(%)
7.5 細胞特異的デリバリープラットフォーム
7.5.1 細胞特異的デリバリープラットフォーム地域別予測、2022年～2032年 (US$ Mn)
7.5.2 細胞特異的デリバリープラットフォーム地域別市場シェア、2022-2032年(%)
7.6 キャリアを介したデリバリープラットフォーム
7.6.1 キャリア媒介型デリバリープラットフォーム地域別市場、2022-2032年 (US$ Mn)
7.6.2 キャリア媒介型プラットフォーム地域別市場シェア、2022年～2032年(%)
7.6.3 キャリア媒介型デリバリープラットフォーム市場：タイプ別、2022年～2032年 (US$ Mn)
7.6.3.1 ウィルスベクター
7.6.3.1.1.1 ウイルスベクター地域別市場、2022-2032 (US$ Mn)
7.6.3.1.1.2 ウイルスベクター地域別市場シェア、2022-2032年(%)
7.6.3.2 非ウイルス性
7.6.3.2.1 非ウイルス性ベクター地域別市場、2022-2032年(US$ Mn)
7.6.3.2.2 非ウイルス剤地域別市場シェア、2022-2032年(%)
7.6.3.3 非ウイルス性ベクターの種類別市場、2022-2032年 (US$ Mn)
7.6.3.3.1.1 リピッドナノパーティクル（LNP）
7.6.3.3.1.2 ペプチドベースベクター
7.6.3.3.1.3 ポリマーベースベクター

8 世界のmRNAワクチンと治療薬市場：投与経路別
8.1 主な調査結果
8.2 運用経路別セグメントの成長展望
8.3 mRNAワクチン・治療薬の世界市場規模予測・予測（デリバリールート別）：2022年＆2032年
8.4 皮内投与
8.4.1 皮内投与ルート地域別予測、2022年～2032年 (US$ Mn)
8.4.2 皮内投与経路の地域別予測、2022年～2032年 (%)
8.5 皮下投与
8.5.1 皮下投与経路の地域別予測、2022-2032年 (US＄ Mn)
8.5.2 皮下投与ルート地域別予測、2022-2032年（%） 5.1 皮下投与ルート地域別予測、2022-2032年（US$ Mn
8.6 筋肉内投与
8.6.1 筋肉内投与ルートの地域別予測、2022-2032 (US$ Mn)
8.6.2 筋肉内投与ルート地域別予測、2022-2032年（%） 6.2 筋肉内投与ルート地域別予測、2022-2032年（%)
8.7 静脈内投与
8.7.1 静脈内投与経路の地域別予測、2022-2032年（US$ Mn）
8.7.2 静脈内投与経路の地域別予測、2022-2032年（%）。
8.8 イントラノーダル
8.8.1 頭蓋内投与経路の地域別予測、2022-2032 (US$ Mn)
8.8.2 mRNAの経口投与ルート地域別予測、2022-2032年(%)

9 世界のmRNAベース治療薬とワクチン市場：エンドユーザー別
9.1 主な調査結果
9.2 エンドユーザーセグメントの成長展望
9.3 mRNAワクチン＆治療薬の世界市場規模予測（エンドユーザー別）2022年＆2032年
9.4 研究機関
9.4.1 研究機関市場予測、エンドユーザー別、地域別、2022年～2032年 (US$ Mn)
9.4.2 研究機関市場地域別シェア、2022年～2032年(%)
9.5 病院・診療所セグメントの市場予測、2022年～2032年
9.5.1 ホスピタル＆クリニックの地域別市場予測、2022-2032年 (US$ Mn)
9.5.2 ホスピタル＆クリニックの地域別市場予測（2022年～2032年）(%)

10 世界のmRNAワクチンと治療薬市場分析：地域別
10.1 主な調査結果
10.2 地域別市場規模の推定と予測
10.3 COVID-19の影響度分析。回復シナリオ(V, U, W, L)

11 北米のmRNAワクチンと治療薬市場分析
11.1 主な調査結果
11.2 北米のmRNAワクチンと治療薬市場の魅力度指数
11.3 北米mRNAワクチンと治療薬国別市場：2022年、2027年、2032年（US$ mn）
11.4 北米mRNAワクチンと治療薬国別市場規模予測・予想
11.5 北米mRNAワクチンと治療薬市場タイプ別市場規模予測・予測
11.6 北米mRNAワクチンと治療薬市場ベクタープラットフォーム別市場規模予測・予想
11.7 北米mRNAワクチンと治療薬市場のベクターデリバリープラットフォーム別市場規模予測・予想
11.7.1 北米mRNAワクチンと治療薬市場キャリア媒介型ベクターデリバリープラットフォーム別市場規模予測・予想
11.7.1.1 北米mRNAワクチンと治療薬市場規模予測・予測：非ウイルスベクターデリバリープラットフォーム別
11.8 北米mRNAワクチンと治療薬市場規模予測・用途別予測
11.9 北米mRNAワクチンと治療薬の市場規模予測：投与経路別
11.10 北米mRNAワクチンと治療薬市場のエンドユーザー別市場規模予測・予想
11.11 北米にmRNAワクチンと治療薬の国別市場規模予測・予想
11.11.1 米国
11.11.2 カナダ

12 欧州のmRNAワクチンと治療薬市場分析
12.1 主な調査結果
12.2 欧州mRNAワクチンと治療薬市場魅力度指数
12.3 欧州mRNAワクチンと治療薬国別市場 2022年、2027年、2032年 (US$ mn)
12.4 欧州mRNAワクチンと治療薬国別市場規模予測・予測
12.5 欧州mRNAワクチンと治療薬市場タイプ別市場規模予測・予測
12.6 欧州mRNAワクチンと治療薬市場ベクタープラットフォーム別市場規模予測・予測
12.7 欧州mRNAワクチンと治療薬市場ベクターデリバリープラットフォーム別市場規模予測・予想
12.7.1 欧州mRNAワクチンと治療薬市場キャリアベクターデリバリープラットフォーム別市場規模予測・予想
12.7.1.1 欧州mRNAワクチンと治療薬ク市場規模予測・予測：非ウィルスベクターデリバリープラットフォーム別
12.8 欧州mRNAワクチンと治療薬市場規模予測・用途別予測
12.9 欧州mRNAワクチンと治療薬市場規模予測：送達ルート別
12.10 欧州mRNAワクチンと治療薬市場エンドユーザー別市場規模予測・予測
12.11 欧州mRNAワクチンと治療薬市場規模予測・予測（国別
12.11.1 ドイツ
12.11.2 イギリス
12.11.3 フランス
12.11.4 スペイン
12.11.5 イタリア
12.11.6 その他の欧州

13 アジア太平洋地域のmRNAワクチンと治療薬市場分析
13.1 主な調査結果
13.2 アジア太平洋地域のmRNAワクチンと治療薬市場の魅力度指数
13.3 アジア太平洋地域のmRNAワクチンと治療薬の国別市場規模予測（2022年、2027年、2032年）（US$ Mn
13.4 アジア太平洋地域のmRNAワクチンと治療薬の国別市場規模予測・予想
13.5 アジア太平洋地域のmRNAワクチンと治療薬市場の種類別市場規模予測・予測
13.6 アジア太平洋地域のmRNAワクチンとと治療薬セラピューティック市場のベクタープラットフォーム別市場規模予測・予想
13.7 アジア太平洋地域のmRNAワクチンと治療薬市場のベクターデリバリープラットフォーム別規模予測・予想
13.7.1 アジア太平洋地域のmRNAワクチンと治療薬市場規模の推定と予測：キャリア媒介型ベクターデリバリープラットフォーム別
13.7.1.1 アジア太平洋地域のmRNAワクチンと治療薬市場規模の推定と予測：キャリアを介した非ウイルスベクターデリバリープラットフォーム別
13.8 アジア太平洋地域のmRNAワクチンと治療薬市場の用途別市場規模予測・予想
13.9 アジア太平洋地域のmRNAワクチンと治療薬の市場規模予測：投与ルート別
13.10 アジア太平洋地域のmRNAワクチンと治療薬のエンドユーザー別市場規模予測・予想
13.11 アジア太平洋地域のmRNAワクチンと治療薬の国別市場規模予測・予想
13.11.1 中国
13.11.2 インド
13.11.3 日本
13.11.4 韓国
13.11.5 オーストラリア
13.11.6 その他のアジア太平洋地域

14 ラテンアメリカのmRNAワクチンと治療薬市場分析
14.1 主な調査結果
14.2 ラテンアメリカのmRNAワクチンと治療薬市場魅力度指数
14.3 ラテンアメリカのmRNAワクチンと治療薬国別市場：2022年、2027年、2032年（US$ Mn）
14.4 中南米の国別mRNAワクチンと治療薬市場規模予測・予測
14.5 中南米のmRNAワクチンと治療薬市場の種類別市場規模予測・予想
14.6 中南米のmRNAワクチンと治療薬市場のベクタープラットフォーム別市場規模予測・予想
14.7 中南米のmRNAワクチンと治療薬市場のベクターデリバリープラットフォーム別サイズ予測・予想
14.7.1 ラテンアメリカのmRNAワクチンと治療薬市場規模予測・予測：キャリア媒介型ベクターデリバリープラットフォーム別
14.7.1.1 中南米のmRNAワクチンと治療薬市場規模予測：キャリアを介した非ウイルスベクターデリバリープラットフォーム別
14.8 中南米mRNAワクチンと治療薬市場規模予測・用途別予測
14.9 中南米mRNAワクチンと治療薬市場の送達ルート別サイズ予測・予測
14.10 中南米のmRNAワクチンと治療薬市場のエンドユーザー別市場規模予測・予想
14.10.1 ブラジル
14.10.2 アルゼンチン
14.10.3 メキシコ
14.10.4 ラテンアメリカの残りの地域

15 中東・アフリカのmRNAワクチンと治療薬市場分析
15.1 主な調査結果
15.2 中東・アフリカのmRNAワクチンと治療薬市場魅力度指数
15.3 中東・アフリカのmRNAワクチンと治療薬国別市場：2022年、2027年、2032年（US$ Mn）
15.4 中東・アフリカ地域 mRNAワクチンと治療薬国別市場規模予測・予測
15.5 中東・アフリカのmRNAワクチンと治療薬市場のタイプ別市場規模予測・予想
15.6 中東・アフリカ地域のmRNAワクチンと治療薬市場のベクタープラットフォーム別市場規模予測・予想
15.7 中東・アフリカ地域のmRNAワクチンと治療薬市場のベクターデリバリープラットフォーム別市場規模予測・予想
15.7.1 中東・アフリカ地域のmRNAワクチンと治療薬市場規模の推定と予測：キャリア媒介型ベクターデリバリープラットフォーム別
15.7.1.1 中東・アフリカ地域のmRNAワクチンと治療薬市場規模の推定と予測：キャリアを介した非ウイルスベクターデリバリープラットフォーム別
15.8 中東・アフリカ地域のmRNAワクチンと治療薬市場の用途別市場規模予測・予想
15.9 中東・アフリカのmRNAワクチンと治療薬市場の送達ルート別サイズ推定・予測
15.10 中東・アフリカのmRNAワクチンと治療薬市場のエンドユーザー別市場規模予測・予想
15.10.1 サウジアラビア
15.10.2 UAE
15.10.3 トルコ
15.10.4 南アフリカ
15.10.5 その他の中東・アフリカ地域

16 主要企業のプロフィール
16.1 企業シェア分析
16.2 主要事業戦略分析
16.3 アストラゼネカPLC
16.3.1 会社概要
16.3.2 会社概要
16.3.3 財務分析
16.3.3.1 純収益、2017-2021年
16.3.3.2 コア営業利益、2017年-2021年
16.3.3.3 R＆D、2017-2021年
16.3.3.4 地域別医薬品市場の売上高、2017-2021年
16.3.4 アストラゼネカCOVIDワクチン売上高、2021年
16.3.5 アストラゼネカPLC:開発パイプライン
16.3.6 戦略的な展望
16.4 モデナ
16.4.1 企業スナップショット
16.4.2 会社概要
16.4.3 財務分析
16.4.3.1 純収益、2017-2021年
16.4.3.2 R＆D費、2017年～2021年
16.4.3.3 地域別医薬品市場シェア、2021年
16.4.4 Moderna:ワクチン・治療薬開発パイプライン
16.4.5 戦略的な展望
16.5 CureVac N.V.
16.5.1 企業スナップショット
16.5.2 会社概要
16.5.3 財務分析
16.5.3.1 純収益、2018-2021年
16.5.3.2 CureVac N.V.の契約顧客からの収益：2018年-2021年
16.5.3.3 R＆D費用、2018年〜2021年
16.5.3.4 地域別医薬品市場シェア（%）、2018年〜2021年
16.5.4 CureVac N.V.社。ワクチン・治療薬開発パイプライン
16.5.5 戦略的な展望
16.6 バイオテックSE
16.6.1 企業スナップショット
16.6.2 会社概要
16.6.3 財務分析
16.6.3.1 純収益、2018-2021年
16.6.3.2 BioNTech SEのR＆D共同研究からの収益。2018-2021
16.6.3.3 R＆D費用、2018年～2021年
16.6.3.4 共同研究による地域別売上高（百万米ドル）、2018-2021年
16.6.4 BioNTech SE：ワクチン＆治療薬開発パイプライン
16.6.5 戦略的な展望
16.7 ファイザー株式会社
16.7.1 企業スナップショット
16.7.2 会社概要
16.7.3 財務分析
16.7.3.1 純収益、2017年-2021年
16.7.3.2 純利益：2017年-2021年
16.7.4 ファイザー株式会社：mRNAワクチンの承認状況
16.7.5 戦略的な展望
16.8 GSK Plc.
16.8.1 企業スナップショット
16.8.2 会社概要
16.8.3 財務分析
16.8.3.1 純収益、2017-2021年
16.8.3.2 R＆D費用：2017年-2021年
16.8.3.3 地域別収益、セグメント別、2019年-2021年
16.8.3.4 地域別売上高（百万米ドル）、2018年-2021年
16.8.4 GSK Inc.：mRNAワクチンのパイプライン状況
16.8.5 戦略的な展望
16.9 アークトゥルス・セラピューティクス・ホールディングス社
16.9.1 企業スナップショット
16.9.2 会社概要
16.9.3 財務分析
16.9.3.1 純収益、2019-2021年
16.9.3.2 Arcturus Therapeutics Holdings Inc.、共同開発収益（2019-2021年）
16.9.4 Arcturus Therapeutics Holdings Inc: mRNAワクチン・パイプラインの状況
16.9.5 戦略的な展望
16.10 トランスレートバイオ（現サノフィ社）
16.10.1 企業スナップショット
16.10.2 会社概要
16.10.3 財務分析
16.10.3.1 純収益、2018-2020年
16.10.3.2 R＆D費（百万米ドル）、2018年-2020年
16.10.4 トランスレートバイオ（サノフィ社）：mRNAワクチンパイプラインの状況
16.10.5 戦略的な展望
16.11 サノフィ
16.11.1 企業スナップショット
16.11.2 会社概要
16.11.3 財務分析
16.11.3.1 純収益、2017-2021年
16.11.3.2 R＆D費用（百万米ドル）、2017年-2021年
16.11.3.3 サノフィ社、純利益（2017年-2021年）
16.11.4 サノフィ社：mRNAワクチンのパイプライン状況
16.11.5 戦略的な展望
16.12 イーアールエヌエー
16.12.1 企業スナップショット
16.12.2 会社概要
16.12.3 パートナーシップ/戦略的共同研究
16.12.4 戦略的展望
16.13 ステミルナ・セラピューティクス
16.13.1 企業スナップショット
16.13.2 会社概要
16.13.3 Stemirna: mRNA ワクチンパイプラインの状況
16.14 カルテジアン・セラピューティクス
16.14.1 企業スナップショット
16.14.2 会社概要
16.14.3 カルテジアン：mRNAワクチンのパイプラインの現況
16.14.4 戦略的な展望
16.15 エスリス
16.15.1 企業スナップショット
16.15.2 会社概要
16.15.3 エトリス：mRNAワクチンのパイプラインの状況
16.15.4 戦略的展望

17 結論と提言
17.1 ビジョンゲインからの結論
17.2 市場関係者への提言

表の一覧
Table 1 Global mRNA Vaccines & Therapeutics Market Snapshot, 2022 & 2032 (US$ million, CAGR %)
Table 2 Global mRNA vaccines & therapeutics market : Phase III
Table 3 Global mRNA vaccines & therapeutics market : Companies & Delivery Platforms
Table 4 Global mRNA vaccines & therapeutics Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario
Table 5 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario
Table 6 Global mRNA vaccines & Therapeutic Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario
Table 7 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario
Table 8 Global mRNA vaccines & therapeutics Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 9 Prophylactic Vaccine in Pipeline Analysis
Table 10 Prophylactic vaccines Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 11 mRNA Cancer Vaccine in Pipeline Analysis
Table 12 Therapeutic Vaccine Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 13 mRNA Cancer Vaccine in Pipeline Analysis
Table 14 mRNA Therapeutics Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 15 Global mRNA vaccines & therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %)
Table 16 Cell Therapy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 17 mRNA vaccines & Therapeutics, Gene Editing Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 18 Clinical Trials of mRNA for Protein-Replacement Therapies
Table 19 mRNA vaccines & Therapeutics, Protein Replacement Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 20 Clinical Trials of mRNA for Cancer vaccines and Therapeutic
Table 21 mRNA vaccines & Therapeutics, Cancer Immunotherapy Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 22 Clinical Trials of mRNA for Infectious Diseases
Table 23 mRNA vaccines & Therapeutics, Infectious Diseases Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 24 Global mRNA vaccines & therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 25 Self-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 26 Non-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 27 Global mRNA vaccines & therapeutics Market Forecast by Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 28 Naked Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 29 mRNA Therapeutic & Vaccine Forecast by Cell Specific Delivery
Table 30 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 31 Carrier Mediated Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 32 Carrier Mediated Delivery Platform Market Forecast by Types, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 33 Viral Vector Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 34 Non- Viral Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 35 Non-Viral Vector Market Forecast by Types, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 36 mRNA delivery by Lipid Nanoparticle Platform Clinical trials
Table 37 Lipid Nano Particles Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 38 Global Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 39 Global Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 40 Global mRNA Therapeutic and Vaccine Delivery, By Route of Administration Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 41 Global mRNA vaccines & therapeutics Market Forecast by Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR %)
Table 42 Intradermal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 43 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 44 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 45 Intravenous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 46 Intranodal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 47 Global mRNA vaccines & therapeutics Market Forecast by End Users, 2022-2032 (US$ million, AGR%, CAGR %)
Table 48 Research Organizations Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 49 Hospitals & Clinics Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 50 Global mRNA Vaccines & Therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 51 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario
Table 52 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario
Table 53 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario
Table 54 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario
Table 55 North America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 56 North America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 57 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 58 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 59 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 60 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 61 North America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %)
Table 62 North America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 63 North America mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%)
Table 64 U.S. mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 65 Canada mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 66 Europe mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 67 .Europe mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 68 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 69 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 70 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 71 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 72 Europe mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%)
Table 73 Europe mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 74 Europe mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR %)
Table 75 Germany mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 76 UK mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 77 France mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 78 Spain mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 79 Italy mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 80 Rest of Europe mRNA Vaccines & Therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 81 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 82 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 83 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 84 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 85 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 86 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 87 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %)
Table 88 Asia Pacific mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 89 Asia Pacific mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%)
Table 90 China mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 91 India mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 92 Japan mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 93 South Korea mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 94 Australia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 95 ROA mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 96 Latin America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 97 Latin America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 98 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 99 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 100 .Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 101 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 102 Latin America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%)
Table 103 Latin America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 104 Latin America mRNA Vaccines & Therapeutics market Forecast by End Users-2032 (US$ million, AGR%, CAGR %)
Table 105 Brazil mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 106 Argentina mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 107 Mexico mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 108 Rest of Latin America mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 109 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 110 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 111 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 112 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 113 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 114 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 115 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%)
Table 116 Middle East & Africa mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 117 Middle East & Africa mRNA vaccines & therapeutics Market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%)
Table 118 Saudi Arabia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 119 UAE mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 120 Turkey mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 121 South Africa mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 122 Rest of Middle East mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 123 Key Business Strategies Adopted by Key Players in Global MRNA vaccines & therapeutics market
Table 124 AstraZeneca PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 AstraZeneca PLC: Pipeline Development
Table 126 AstraZeneca PLC : Strategic Outlook
Table 127 Moderna: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Moderna : mRNA Therapeutics & vaccines Pipeline 2022-2032
Table 129 Moderna : Strategic Outlook
Table 130 CureVac N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 CureVac N.V., Revenues from Contract Customers,2018-2021 (US$ million, AGR %)
Table 132 CureVac N.V.: mRNA Therapeutics & Vaccines Pipeline 2022-2032
Table 133 CureVac N.V.: Strategic Outlook
Table 134 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 135 BioNTech SE, Revenues from R&D Collaborations,2018-2021 (US$ million)
Table 136 BioNTech SE: mRNA Therapeutics & Vaccines Pipeline 2022-2032
Table 137 BioNTech SE: Strategic Outlook
Table 138 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 Pfizer Inc.: mRNA Vaccine Approval Status
Table 140 Pfizer Inc.: Strategic Outlook
Table 141 GSK Plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 142 GSK Plc: Revenues, By Segment, 2019-2021 (US$ million, AGR %)
Table 143 GSK Plc: Regional Revenues, 2018-2021 (US$ million)
Table 144 GSK Plc: mRNA Vaccine Approval Status
Table 145 GSK Plc: Strategic Outlook
Table 146 Arcturus Therapeutics Holdings Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 147 Arcturus Therapeutics Holdings Inc.: mRNA Vaccine and Therapeutics Pipeline
Table 148 Arcturus Therapeutics Holdings Inc.: Strategic Outlook
Table 149 Translate Bio ( A Sanofi Company).: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 150 Translate Bio ( A Sanofi Company).: mRNA Vaccine and Therapeutics Pipeline
Table 151 Translate Bio ( A Sanofi Company).: Strategic Outlook
Table 152 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 153 Sanofi: mRNA Vaccine and Therapeutics Pipeline
Table 154 Sanofi: Strategic Outlook
Table 155 eTheRNA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 156 ETheRNA: mRNA Strategic Collaborations
Table 157 ETheRNA: Strategic Outlook
Table 158 Stemirna Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 159 Stemirna Therapeutics: mRNA Strategic Collaborations
Table 160 Cartesian Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 161 Cartesian Therapeutics: mRNA Strategic Collaborations
Table 162 Cartesian : Strategic Outlook
Table 163 Ethris: mRNA Pipeline
Table 164 Ethris: Strategic Outlook

図の一覧
Figure 1 Global mRNA Vaccines & Therapeutics Market Segmentation
Figure 2 Global mRNA vaccines & therapeutics Market Forecast by Region: Market Attractiveness Index
Figure 3 Global mRNA vaccines & therapeutics Market by Therapeutics: Market Attractiveness Index
Figure 4 Global mRNA vaccines & therapeutics Market by Vector Platform: Market Attractiveness Index
Figure 5 Global mRNA vaccines & therapeutics Market by Delivery Platform: Market Attractiveness Index
Figure 6 Global mRNA vaccines & therapeutics Market by Route of Administration: Market Attractiveness Index
Figure 7 Global mRNA vaccines & therapeutics Market by Applications: Market Attractiveness Index
Figure 8 Global mRNA vaccines & therapeutics market by End Users : Market Attractiveness Index
Figure 9 Global mRNA vaccines & therapeutics market Dynamics
Figure 10 Global COVID Impact Analysis: mRNA vaccines & therapeutics Market Recovery Scenarios (US$ million, CAGR %)
Figure 11 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 12 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 13 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 14 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 15 Global mRNA vaccines & therapeutics Market: Porter’s Five Forces Analysis
Figure 16 Global mRNA vaccines & therapeutics Market: PEST Analysis
Figure 17 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Type
Figure 18 Global mRNA vaccines & therapeutics Market Forecast by Type, 2022-2032 (US$ million, AGR %)
Figure 19 Global mRNA vaccines & therapeutics Market Share Forecast by Type, 2022, 2032 (%)
Figure 20 Prophylactic vaccines Market Forecast by Region, 2022-2032 (US$ Mn)
Figure 21 Prophylactic vaccines Market Forecast by Region, 2022-2032 (%)
Figure 22 Therapeutic Vaccine Forecast by Region, 2022-2032 (US$ million)
Figure 23 Therapeutic Vaccine Forecast by Region, 2022-2032 (%)
Figure 24 mRNA Therapeutics Market Forecast by Region, 2022-2032 (US$ million)
Figure 25 mRNA Therapeutics Market Forecast by Region, 2022-2032 (%)
Figure 26 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Applications
Figure 27 Global mRNA vaccines & therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 28 mRNA vaccines & therapeutics Market Share Forecast by Applications, 2022, 2032 (%)
Figure 29 Cell Therapy Market Forecast by Region, 2022-2032 (US$ million)
Figure 30 Cell Therapy Market Share by Region, 2022-2032 (%)
Figure 31 mRNA Vaccine & Therapeutics, By Gene Editing Forecast by Region, 2022-2032 (US$ million)
Figure 32 mRNA Gene Editing Application Market, Forecast by Region, 2022-2032 (%)
Figure 33 mRNA Vaccine & Therapeutics, By Protein Replacement Forecast by Region, 2022-2032 (US$ million)
Figure 34 mRNA Protein Replacement Application Market, Forecast by Region, 2022-2032 (%)
Figure 35 mRNA Vaccine & Therapeutics, By Cancer Immunotherapy Forecast by Region, 2022-2032 (US$ million)
Figure 36 mRNA Cancer Immunotherapy Application Market, Forecast by Region, 2022-2032 (%)
Figure 37 mRNA Vaccine & Therapeutics, By Infectious Diseases Forecast by Region, 2022-2032 (US$ million)
Figure 38 mRNA Infectious Diseases Application Market, Forecast by Region, 2022-2032 (%)
Figure 39 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Vector Platform
Figure 40 Global mRNA vaccines & therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 41 Global mRNA vaccines & therapeutics Market Share Forecast by Vector Platform, 2022, 2032 (%)
Figure 42 Self-Amplifying mRNA Forecast by Region, 2022-2032 (US$ million)
Figure 43 Self-Amplifying mRNA Market, Forecast by Region, 2022-2032 (%)
Figure 44 Non-Amplifying mRNA Forecast by Region, 2022-2032 (US$ million)
Figure 45 Non-Amplifying mRNA Market, Forecast by Region, 2022-2032 (%)
Figure 46 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Delivery Platform
Figure 47 Global mRNA vaccines & therapeutics Market Forecast by Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 48 Global mRNA vaccines & therapeutics Market Share Forecast by Delivery Platform, 2022, 2032 (%)
Figure 49 Naked Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 50 Naked Delivery Platform Market Forecast by Region, 2022-2032(%)
Figure 51 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ million)
Figure 52 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 53 Carrier Mediated Platform Market Forecast by Region, 2022-2032 (US$ million)
Figure 54 Carrier Mediated Delivery Platform Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 55 Viral Vector Market Forecast by Region, 2022-2032 (US$ million)
Figure 56 Viral Vector Market Share Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 57 Non-Viral Market Forecast by Region, 2022-2032 (US$ million)
Figure 58 Non-Viral Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 59 Lipid Nano-Particles Market Forecast by Region, 2022-2032 (US$ million)
Figure 60 Lipid Nano-Particles Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 61 Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ million)
Figure 62 Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 63 Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ million)
Figure 64 Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 65 Global mRNA Vaccines & Therapeutics Market Forecast by Route of Administration 2022, 2027, 2032 (Revenue, CAGR %)
Figure 66 Global mRNA vaccines & therapeutics Market Forecast by Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 67 Global mRNA vaccines & therapeutics Market Share Forecast by Route of Delivery, 2022, 2032 (%)
Figure 68 Intradermal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 69 Intradermal Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 70 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 71 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 72 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 73 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 74 Intravenous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 75 Intravenous Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 76 Intranodal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 77 Global mRNA Intranodal Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 78 Global mRNA vaccines & therapeutics Market Forecast by End-Users 2022, 2027, 2032 (Revenue, CAGR %)
Figure 79 Global mRNA vaccines & therapeutics Market Forecast by End Users, 2022-2032 (US$ million, AGR %)
Figure 80 Global mRNA vaccines & therapeutics Market Share Forecast by End Users, 2022, 2032 (%)
Figure 81 Research Organizations Market Forecast by Region, 2022-2032 (US$ Mn )
Figure 82 Research Organizations Market Share Forecast, by Region, 2022-2032(%)
Figure 83 Hospitals & Clinics Market Forecast, by Region, 2022-2032 (US$ Mn )
Figure 84 Hospitals & Clinics Market Forecast, by Region, 2022-2032(%)
Figure 85 Global mRNA Vaccines & Therapeutics Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR%)
Figure 86 Global mRNA Vaccines & Therapeutics Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 87 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Figure 88 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 89 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 90 Global MRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 91 Global MRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 92 North America mRNA Vaccines & Therapeutics Market Attractiveness Index
Figure 93 North America mRNA Vaccines & Therapeutics market by Region, 2022, 2027 & 2032 (US$ million)
Figure 94 North America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 95 North America mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 96 North America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 97 North America mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 98 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 99 North America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 100 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 101 North America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 102 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 103 North America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 104 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 105 North America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 106 North America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 107 North America mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 108 North America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 109 North America mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 110 North America mRNA vaccines & therapeutics Market Forecast By End Users, 2022-2032 (US$ million, AGR %)
Figure 111 North America mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 112 U.S. mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 113 Canada mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 114 Europe mRNA Vaccines & Therapeutics Market Attractiveness Index,2022
Figure 115 Europe mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ million)
Figure 116 Europe mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 117 Europe mRNA vaccines & therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 118 Europe mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 119 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 120 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 121 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 122 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 123 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 124 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 125 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 126 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 127 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 128 Europe mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 129 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 130 Europe mRNA Vaccines & Therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 131 Europe mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 132 Europe mRNA Vaccines & Therapeutics Market Forecast by End Users-2032 (US$ million, AGR %)
Figure 133 Europe mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 134 Germany mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 135 UK mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 136 France mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 137 Spain mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 138 Italy mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 139 Rest of Europe mRNA Vaccines & Therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 140 Asia Pacific mRNA vaccines and Therapeutics Market Attractiveness Index
Figure 141 Asia Pacific mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million)
Figure 142 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 143 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 144 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 145 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 146 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 147 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 148 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 149 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 150 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 151 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 152 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 153 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 154 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 155 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 156 Asia Pacific mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 157 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 158 Asia Pacific mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR %)
Figure 159 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 160 China mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 161 India mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 162 Japan mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 163 South Korea mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 164 Australia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 165 ROA mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 166 Latin America mRNA vaccines and Therapeutics Market Attractiveness Index
Figure 167 Latin America mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million)
Figure 168 Latin America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 169 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 170 Latin America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 171 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 172 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 173 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 174 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 175 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 176 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 177 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 178 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 179 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 180 Latin America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 181 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 182 Latin America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 183 Latin America mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 184 Latin America mRNA Vaccines & Therapeutics Market Forecast by End Users, 2032 (US$ million, AGR %)
Figure 185 Latin America mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 186 Brazil mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 187 Argentina mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 188 Mexico mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 189 Rest of Latin America mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 190 Middle East & Africa mRNA vaccines and Therapeutics Market Attractiveness Index
Figure 191 Middle East & Africa mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million)
Figure 192 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 193 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 194 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 195 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 196 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 197 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 198 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 199 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 200 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 201 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 202 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 203 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 204 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 205 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 206 Middle East & Africa mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 207 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 208 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by End Users, 2032 (US$ million, AGR %)
Figure 209 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 210 Saudi Arabia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 211 UAE mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 212 Turkey mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 213 South Africa mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 214 Rest of Middle East mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 215 Global mRNA vaccines & therapeutics market: Company Share Analysis, 2021
Figure 216 AstraZeneca PLC: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 217 AstraZeneca PLC Holdings AG: Core Operating Profit, 2017-2021 (US$ million, AGR%)
Figure 218 AstraZeneca PLC: R&D, 2017-2021 (US$ million, AGR%)
Figure 219 AstraZeneca PLC: Regional Pharmaceutical Revenues, By Region 2017-2021 (US$ million)
Figure 220 AstraZeneca PLC: Revenues, By Disease Area, 2021 (% share)
Figure 221 Moderna: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 222 Moderna, Revenues By Collaboration 2017-2021 (US$ million)
Figure 223 Moderna: R&D Expense, 2017-2021 (US$ million, AGR%)
Figure 224 Moderna: Regional Pharmaceutical Market Shares, 2021 (%)
Figure 225 CureVac N.V.: Net Revenue, 2018-2021 (US$ million, AGR %)
Figure 226 CureVac N.V.: R&D Expense, 2018-2021 (US$ million, AGR %)
Figure 227 CureVac N.V.: Regional Pharmaceutical Market Shares, 2018-2021 (%)
Figure 228 BioNTech SE: Net Revenue, 2018-2021 (US$ million, AGR %)
Figure 229 BioNTech SE: R&D Expense, 2018-2021 (US$ million, AGR %)
Figure 230 BioNTech SE: Regional Revenues by Collaborations, 2018-2021 (US$ million)
Figure 231 Pfizer Inc: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 232 Pfizer Inc. Net Income: 2017-2021 (US$ million, AGR %)
Figure 233 GSK Plc,: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 234 GSK Plc. R&D Expense: 2017-2021 (US$ million, AGR %)
Figure 235 Arcturus Therapeutics Holdings Inc., Net Revenues=, 2019-2021 (US$ million, AGR %)
Figure 236 Arcturus Therapeutics Holdings Inc.: Collaboration Revenues, 2019-2021 (US$ million)
Figure 237 Translate Bio (A Sanofi Company), Net Revenues from Collaborations 2018-2020 (US$ million, AGR %)
Figure 238 Translate Bio ( A Sanofi Company).: R&D Expense, 2018-2020 (US$ million)
Figure 239 Sanofi, Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 240 Sanofi: R&D Expense, 2017-2021 (US$ million)
Figure 241 Sanofi: Net Income, 2017-2021 (US$ million)
Figure 242 Sanofi: Business Segments Revenue, 2018-2021 (US$ million)

ページTOPに戻る

Table of Contents

Summary

この調査レポートは世界のmRNAワクチンと治療薬市場を調査し、タイプ別、ベクター別、ベクタープラットフォーム別、キャリア媒介別、配送経路別、用途別、エンドユーザー別、地域別に2022年から2032年までの予測結果を掲載しています。また関連企業情報を提供しています。

主な掲載内容（目次より抜粋）

レポート概要
エグゼクティブサマリー
市場概要
世界のmRNAワクチンと治療薬市場：タイプ別
mRNAワクチンと治療薬市場分析：用途別
mRNAワクチンと治療薬市場：ベクタープラットフォーム別
世界のmRNAワクチンと治療薬市場：デリバリーモード別
世界のmRNAワクチンと治療薬市場：投与経路別
世界のmRNAベースの治療薬とワクチン市場：エンドユーザー別
世界のmRNAワクチンと治療薬市場分析：地域別
北米のmRNAワクチンと治療薬市場分析
欧州のmRNAワクチンと治療薬市場分析
アジア太平洋地域のmRNAワクチンと治療薬市場分析
ラテンアメリカのmRNAワクチンと治療薬市場分析
中東・アフリカのmRNAワクチンと治療薬市場分析
主要企業のプロフィール

Report Details

The mRNA Vaccines & Therapeutics Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

CDMOs Seizing Opportunities in the Newly Commercializing mRNA Market
A successful application of mRNA technology for COVID-19 has reinvigorated biopharmaceutical companies to further explore opportunities of this technology for other diseases. There has been a significant increase in therapeutic mRNA programs that are focused on mRNA and its delivery platform, which is the major challenge for the delivery of mRNA into the cells. The Contract Development and Manufacturing Organisations (CDMOs) have also been compelled to ramp in their production capabilities to meet this surge in demand. Many existing CDMOs have made huge capital investments through developing and upgrading their manufacturing capabilities and processes to match GMP standards for vaccine development. These companies are making strategic partnerships and acquisitions to fortify their mRNA manufacturing technologies. For instance, Korea-based Samsung Biologics had signed an agreement with Moderna in May 2021 for aseptic fill-finish and packaging and labeling of Moderna’s COVID-19 mRNA vaccine. In August 2021 Samsung Biologics announced its plan in three areas which included capacity expansion setting up an R&D center in the U.S. for support of its clients at a global scale, and expansion of the platform to support diverse applications.

What Questions Should You Ask before Buying a Market Research Report?
• How is the mRNA vaccines & therapeutics market evolving?
• What is driving and restraining the mRNA vaccines & therapeutics market?
• How will each mRNA vaccines & therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each mRNA vaccines & therapeutics submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading mRNA vaccines & therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the mRNA vaccines & therapeutics projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of mRNA vaccines & therapeutics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the mRNA Vaccines & Therapeutics market?
• Where is the mRNA vaccines & therapeutics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the mRNA Vaccines & Therapeutics market today, and over the next 10 years:
• Our 411-page report provides 164 tables and 242 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the mRNA Vaccines & Therapeutics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

The report delivers exclusive COVID-19 variations and economic data specific to your market.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising mRNA Vaccines & Therapeutics recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

mRNA Vaccines & Therapeutics Market by Types
• mRNA Prophylactic Vaccines
• Therapeutics Vaccines
• mRNA Therapeutics

mRNA Vaccines & Therapeutics Market by Vectors
• Self-amplifying mRNA
• Non-amplifying mRNA

mRNA Vaccines & Therapeutics Market by Vector Delivery Platforms
• Naked mRNA
• Cell Specific
• Carrier Mediated
– Viral
– Non-Viral (Polymer-based Vectors, Lipid Nanoparticles, Peptide-based Vectors)

mRNA Vaccines & Therapeutics Market by Route of Administration
• Intramuscular
• Intravenous
• Intradermal
• Subcutaneous
• Intranodal

mRNA Vaccines & Therapeutics Market by Application
• Cell Therapy
• Protein Replacement Therapy
• Gene Editing
• Cancer Immunotherapy
• Infectious Diseases (including COVID-19)

mRNA Vaccines & Therapeutics Market by End-Users
• Hospitals & Clinics
• Research Organizations

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA
• Saudi Arabia
• UAE
• Turkey
• Rest of MEA

The report also includes profiles and for some of the leading companies in the mRNA Vaccines & Therapeutics Market Report 2022-2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AstraZeneca PLC
• Moderna
• CureVac N.V.
• BioNTech SE
• Pfizer Inc.,
• GSK PLC
• Arcturus Therapeutics Holding Inc.
• Translate Bio (now a Sanofi Company)
• Sanofi
• eTheRNA
• Stemirna Therapeutics
• Cartesian Therapeutics
• Ethris

Overall world revenue for mRNA Vaccines & Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$64,338 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the mRNA Vaccines & Therapeutics Market, 2022 to 2032 report help you?
In summary, our 410+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for mRNA Vaccines & Therapeutics Market, 2022 to 2032 Market, with forecasts for services, company size, drug type, and therapeutic area each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for four regional and 22 key national markets – See forecasts for the mRNA Vaccines & Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the mRNA Vaccines & Therapeutics Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the mRNA Vaccines & Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to mRNA Vaccines & Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Growing Diverse Applications of mRNA Post COVID-19 Vaccine Success
3.2.1.2 Significant Research Funding to Boost Market Growth
3.2.1.3 Technological Advances Driving the Market Growth
3.2.2 Market Restraining Factors
3.2.2.1 Scalability and Cost-Effectiveness is Still a Major Bottleneck
3.2.3 Market Opportunities
3.2.3.1 mRNA Cancer Vaccines
3.2.3.2 Analytics, Machine Learning and Cloud Data Warehousing
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat of Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political Factors
3.5.2 Economic Factors
3.5.3 Social Factors
3.5.4 Technological Factors

4 Global mRNA vaccines & therapeutics Market, By Type
4.1 Key Findings
4.2 Type Segment Growth Prospects
4.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Type
4.4 Prophylactic vaccines
4.4.1 Market Size by Region, 2022-2032 (US$ Mn)
4.4.2 Market Share by Region, 2022-2032 (%)
4.5 Therapeutic Vaccines Market
4.5.1 Therapeutics Vaccines Market Forecast by Region, 2022-2032 (US$ Mn)
4.5.2 Therapeutic Vaccine Forecast by Region, 2022-2032 (%)
4.6 mRNA Therapeutics Market Forecast
4.6.1 mRNA Therapeutics Market Forecast by Region 2022-2032 (US$ Mn)
4.6.2 mRNA Therapeutics Market by Region, 2022-2032 (%)

5 mRNA Vaccines & Therapeutics Market Analysis by Applications
5.1 Key Findings
5.2 Applications Segment Growth Prospects
5.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Applications
5.4 mRNA vaccines & therapeutics Market Share by Applications, 2022 & 2032
5.5 Cell Therapy
5.5.1 Cell Therapy Market Forecast by Region, 2022-2032 (US$ Mn)
5.5.2 Cell Therapy Market Share by Region, 2022-2032 (%)
5.6 Gene Editing
5.6.1 Gene Editing Market Forecast by Region, 2022-2032 (US$ Mn)
5.6.2 Gene Editing Market Share by Region, 2022-2032 (%)
5.7 Protein Replacement Therapy
5.7.1 Protein Replacement Market Forecast by Region, 2022-2032 (US$ Mn)
5.7.2 Protein Replacement Market Share by Region, 2022-2032 (%)
5.8 Cancer Immunotherapy
5.8.1 Cancer Immunotherapy Market Forecast by Region, 2022-2032 (US$ Mn)
5.8.2 Cancer Immunotherapy Market Share by Region, 2022-2032 (%)
5.9 Infectious Diseases
5.9.1 Infectious Diseases Market Forecast by Region, 2022-2032 (US$ Mn)
5.9.2 mRNA Infectious Diseases Application Market Share by Region, 2022-2032 (%)

6 mRNA Vaccine & Therapeutics Market, By Vector Platform
6.1 Key Findings
6.2 Vector Platform Segment Growth Prospects
6.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast by Vector Platform
6.4 Global mRNA vaccines & therapeutics Market Share by Vector Platforms, 2022 & 2032
6.5 Self-Amplifying mRNA
6.5.1 Self-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ Mn)
6.5.2 Self-Amplifying mRNA Market Share by Region, 2022-2032 (%)
6.6 Non-Amplifying (Conventional) mRNA
6.6.1 Non-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ Mn)
6.6.2 Non-Amplifying mRNA Market Share by Region, 2022-2032 (%)

7 Global mRNA Vaccines & Therapeutics Market, By Delivery Mode
7.1 Key Findings
7.2 Delivery Platform Segment Growth Prospects
7.3 Global mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Delivery Platform, 2022 & 2032
7.4 Naked mRNA Delivery
7.4.1 Naked Delivery Platform Forecast by Region, 2022-2032 (US$ Mn)
7.4.2 Naked Delivery Platform Market Share by Region, 2022-2032 (%)
7.5 Cell-Specific Delivery Platform
7.5.1 Cell Specific Delivery Platform by Region, 2022-2032 (US$ Mn)
7.5.2 Cell Specific Delivery Platform Market Share by Region, 2022-2032 (%)
7.6 Carrier Mediated
7.6.1 Carrier Mediated Delivery Platform Market by Region, 2022-2032 (US$ Mn)
7.6.2 Carrier Mediated Platform Market Share by Region, 2022-2032 (%)
7.6.3 Carrier Mediated Delivery Platform Market by Types, 2022-2032 (US$ Mn)
7.6.3.1 Viral Vector
7.6.3.1.1.1 Viral Vector Market by Region, 2022-2032 (US$ Mn)
7.6.3.1.1.2 Viral Vector Market Share by Region, 2022-2032 (%)
7.6.3.2 Non-Viral
7.6.3.2.1 Non-Viral Market by Region, 2022-2032 (US$ Mn)
7.6.3.2.2 Non-Viral Market Share by Region, 2022-2032 (%)
7.6.3.3 Non-Viral Vector Market by Types, 2022-2032 (US$ Mn)
7.6.3.3.1.1 Lipid Nanoparticles (LNP)
7.6.3.3.1.2 Peptide-based Vectors
7.6.3.3.1.3 Polymer-based Vectors

8 Global mRNA Vaccines & Therapeutics Market, By Route of Delivery
8.1 Key Findings
8.2 Route of Delivery Segment Growth Prospects
8.3 Global mRNA vaccines & therapeutics Market Size Estimation and Forecast, by Route of Delivery, 2022 & 2032
8.4 Intradermal
8.4.1 Intradermal Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
8.4.2 Intradermal Route of Delivery Forecast by Region, 2022-2032 (%)
8.5 Subcutaneous
8.5.1 Subcutaneous Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
8.5.2 Subcutaneous Route of Delivery Forecast by Region, 2022-2032 (%)
8.6 Intramuscular
8.6.1 Intramuscular Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
8.6.2 Intramuscular Route of Delivery Forecast by Region, 2022-2032 (%)
8.7 Intravenous
8.7.1 Intravenous Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
8.7.2 Intravenous Route of Delivery Forecast by Region, 2022-2032 (%)
8.8 Intranodal
8.8.1 Intranodal Route of Delivery Forecast by Region, 2022-2032 (US$ Mn)
8.8.2 mRNA Intranodal Route of Delivery Forecast by Region, 2022-2032 (%)

9 Global mRNA Based Therapeutics and Vaccine Market by End-User
9.1 Key Findings
9.2 End Users Segment Growth Prospects
9.3 Global mRNA vaccines & therapeutics Market Size Estimation, by End Users, 2022 & 2032
9.4 Research Organizations
9.4.1 Research Organizations Market Forecast, By End Users, by Region, 2022-2032 (US$ Mn)
9.4.2 Research Organizations Market Share by Region, 2022-2032 (%)
9.5 Hospitals & Clinics Segment Market Forecast, 2022-2032
9.5.1 Hospitals & Clinics Market Forecast by Region, 2022-2032 (US$ Mn)
9.5.2 Hospitals & Clinics Market Forecast, by Region, 2022-2032 (%)`

10 Global mRNA vaccines & therapeutics Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast
10.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)

11 North America mRNA Vaccines & Therapeutics Market Analysis
11.1 Key Findings
11.2 North America mRNA Vaccines & Therapeutics Market Attractiveness Index
11.3 North America mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
11.4 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
11.5 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
11.6 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
11.7 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
11.7.1 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform
11.7.1.1 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Non-Viral Vector Delivery Platform
11.8 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
11.9 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
11.10 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users
11.11 North America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Country
11.11.1 U.S.
11.11.2 Canada

12 Europe mRNA Vaccines & Therapeutics Market Analysis
12.1 Key Findings
12.2 Europe mRNA Vaccines & Therapeutics Market Attractiveness Index
12.3 Europe mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ mn)
12.4 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
12.5 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
12.6 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
12.7 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
12.7.1 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Vector Delivery Platform
12.7.1.1 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Non-Viral Vector Delivery Platform
12.8 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
12.9 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
12.10 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users
12.11 Europe mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by Country
12.11.1 Germany
12.11.2 U.K.
12.11.3 France
12.11.4 Spain
12.11.5 Italy
12.11.6 Rest of Europe

13 Asia Pacific mRNA Vaccines & Therapeutics Market Analysis
13.1 Key Findings
13.2 Asia Pacific mRNA Vaccines & Therapeutics Market Attractiveness Index
13.3 Asia Pacific mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn)
13.4 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
13.5 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
13.6 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
13.7 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
13.7.1 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform
13.7.1.1 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform
13.8 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
13.9 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
13.10 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users
13.11 Asia Pacific mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
13.11.1 China
13.11.2 India
13.11.3 Japan
13.11.4 South Korea
13.11.5 Australia
13.11.6 Rest of Asia Pacific

14 Latin America mRNA Vaccines & Therapeutics Market Analysis
14.1 Key Findings
14.2 Latin America mRNA Vaccines & Therapeutics Market Attractiveness Index
14.3 Latin America mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn)
14.4 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
14.5 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
14.6 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
14.7 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
14.7.1 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform
14.7.1.1 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform
14.8 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
14.9 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
14.10 Latin America mRNA Vaccines & Therapeutics Market Size Estimation and Forecast, by End-Users
14.10.1 Brazil
14.10.2 Argentina
14.10.3 Mexico
14.10.4 Rest of Latin America

15 Middle East & Africa mRNA Vaccine & Therapeutics Market Analysis
15.1 Key Findings
15.2 Middle East & Africa mRNA Vaccines & Therapeutics Market Attractiveness Index
15.3 Middle East & Africa mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ Mn)
15.4 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Country
15.5 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Types
15.6 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Platform
15.7 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Vector Delivery Platform
15.7.1 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Vector Delivery Platform
15.7.1.1 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Carrier Mediated Non-Viral Vector Delivery Platform
15.8 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Applications
15.9 Middle East & Africa mRNA Vaccines & Therapeutics Market Size Estimation and Forecast by Route of Delivery
15.10 Middle East & Africa mRNA vaccines & therapeutics Market Size Estimation and Forecast, by End-Users
15.10.1 Saudi Arabia
15.10.2 UAE
15.10.3 Turkey
15.10.4 South Africa
15.10.5 Rest of Middle East & Africa

16 Company Profiles
16.1 Company Share Analysis
16.2 Key Business Strategy Analysis
16.3 AstraZeneca PLC
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Net Revenue, 2017-2021
16.3.3.2 Core Operating Profit, 2017-2021
16.3.3.3 R&D, 2017-2021
16.3.3.4 Regional Pharmaceutical Market Revenue, 2017-2021
16.3.4 AstraZeneca: COVID Vaccine Sales, 2021
16.3.5 AstraZeneca PLC: Development Pipeline
16.3.6 Strategic Outlook
16.4 Moderna
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2017-2021
16.4.3.2 R&D Expense, 2017-2021
16.4.3.3 Regional Pharmaceutical Market Shares, 2021
16.4.4 Moderna: Vaccines & Therapeutics Development Pipeline
16.4.5 Strategic Outlook
16.5 CureVac N.V.
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2018-2021
16.5.3.2 CureVac N.V. Revenues from Contract Customers: 2018-2021
16.5.3.3 R&D Expense, 2018-2021
16.5.3.4 Regional Pharmaceutical Market Shares (%), 2018-2021
16.5.4 CureVac N.V.: Vaccines & Therapeutics Development Pipeline
16.5.5 Strategic Outlook
16.6 BioNTech SE
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2018-2021
16.6.3.2 BioNTech SE Revenues from R&D Collaborations: 2018-2021
16.6.3.3 R&D Expense, 2018-2021
16.6.3.4 Regional Revenues by Collaborations (US$ Million), 2018-2021
16.6.4 BioNTech SE: Vaccines & Therapeutics Development Pipeline
16.6.5 Strategic Outlook
16.7 Pfizer Inc.
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Net Revenue, 2017-2021
16.7.3.2 Net Income: 2017-2021
16.7.4 Pfizer Inc.: mRNA Vaccine Approval Status
16.7.5 Strategic Outlook
16.8 GSK Plc.
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Net Revenue, 2017-2021
16.8.3.2 R&D Expense: 2017-2021
16.8.3.3 Geographic Revenues, By Segment, 2019-2021
16.8.3.4 Regional Revenues (US$ Million), 2018-2021
16.8.4 GSK Inc.: mRNA Vaccine Pipeline Status
16.8.5 Strategic Outlook
16.9 Arcturus Therapeutics Holdings Inc.
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Financial Analysis
16.9.3.1 Net Revenue, 2019-2021
16.9.3.2 Arcturus Therapeutics Holdings Inc., Collaboration Revenues (2019-2021)
16.9.4 Arcturus Therapeutics Holdings Inc: mRNA Vaccine Pipeline Status
16.9.5 Strategic Outlook
16.10 Translate Bio ( now A Sanofi Company)
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2018-2020
16.10.3.2 R&D Expense (US$ Million), 2018-2020
16.10.4 Translate Bio (a Sanofi Company): mRNA Vaccine Pipeline Status
16.10.5 Strategic Outlook
16.11 Sanofi
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Net Revenue, 2017-2021
16.11.3.2 R&D Expense (US$ Million), 2017-2021
16.11.3.3 Sanofi, Net Income (2017-2021)
16.11.4 Sanofi Company: mRNA Vaccine Pipeline Status
16.11.5 Strategic Outlook
16.12 eTheRNA
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Partnerships/ Strategic Collaborations
16.12.4 Strategic Outlook
16.13 Stemirna Therapeutics
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Stemirna: mRNA Vaccine Pipeline Status
16.14 Cartesian Therapeutics
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Cartesian: mRNA Vaccine Pipeline Status
16.14.4 Strategic Outlook
16.15 Ethris
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Ethris: mRNA Vaccine Pipeline Status
16.15.4 Strategic Outlook

17 Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players

List of Tables
Table 1 Global mRNA Vaccines & Therapeutics Market Snapshot, 2022 & 2032 (US$ million, CAGR %)
Table 2 Global mRNA vaccines & therapeutics market : Phase III
Table 3 Global mRNA vaccines & therapeutics market : Companies & Delivery Platforms
Table 4 Global mRNA vaccines & therapeutics Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario
Table 5 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario
Table 6 Global mRNA vaccines & Therapeutic Market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario
Table 7 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario
Table 8 Global mRNA vaccines & therapeutics Market Forecast by Type, 2022-2032 (US$ million, AGR%, CAGR %)
Table 9 Prophylactic Vaccine in Pipeline Analysis
Table 10 Prophylactic vaccines Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 11 mRNA Cancer Vaccine in Pipeline Analysis
Table 12 Therapeutic Vaccine Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 13 mRNA Cancer Vaccine in Pipeline Analysis
Table 14 mRNA Therapeutics Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 15 Global mRNA vaccines & therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %)
Table 16 Cell Therapy Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 17 mRNA vaccines & Therapeutics, Gene Editing Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 18 Clinical Trials of mRNA for Protein-Replacement Therapies
Table 19 mRNA vaccines & Therapeutics, Protein Replacement Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 20 Clinical Trials of mRNA for Cancer vaccines and Therapeutic
Table 21 mRNA vaccines & Therapeutics, Cancer Immunotherapy Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 22 Clinical Trials of mRNA for Infectious Diseases
Table 23 mRNA vaccines & Therapeutics, Infectious Diseases Market By Application Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 24 Global mRNA vaccines & therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 25 Self-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR%)
Table 26 Non-Amplifying mRNA Market Forecast by Region, 2022-2032 (US$ million, AGR%, CAGR %)
Table 27 Global mRNA vaccines & therapeutics Market Forecast by Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 28 Naked Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 29 mRNA Therapeutic & Vaccine Forecast by Cell Specific Delivery
Table 30 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 31 Carrier Mediated Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 32 Carrier Mediated Delivery Platform Market Forecast by Types, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 33 Viral Vector Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 34 Non- Viral Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 35 Non-Viral Vector Market Forecast by Types, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 36 mRNA delivery by Lipid Nanoparticle Platform Clinical trials
Table 37 Lipid Nano Particles Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 38 Global Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 39 Global Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 40 Global mRNA Therapeutic and Vaccine Delivery, By Route of Administration Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 41 Global mRNA vaccines & therapeutics Market Forecast by Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR %)
Table 42 Intradermal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 43 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 44 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 45 Intravenous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 46 Intranodal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 47 Global mRNA vaccines & therapeutics Market Forecast by End Users, 2022-2032 (US$ million, AGR%, CAGR %)
Table 48 Research Organizations Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 49 Hospitals & Clinics Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Table 50 Global mRNA Vaccines & Therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%))
Table 51 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “V” Shaped Recovery Scenario
Table 52 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “U” Shaped Recovery Scenario
Table 53 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “W” Shaped Recovery Scenario
Table 54 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR(%)): “L” Shaped Recovery Scenario
Table 55 North America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 56 North America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 57 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 58 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 59 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 60 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 61 North America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %)
Table 62 North America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 63 North America mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%)
Table 64 U.S. mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 65 Canada mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 66 Europe mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 67 .Europe mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 68 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 69 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 70 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 71 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 72 Europe mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%)
Table 73 Europe mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 74 Europe mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR %)
Table 75 Germany mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 76 UK mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 77 France mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 78 Spain mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 79 Italy mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 80 Rest of Europe mRNA Vaccines & Therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 81 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 82 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 83 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 84 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 85 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 86 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 87 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR %)
Table 88 Asia Pacific mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 89 Asia Pacific mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%)
Table 90 China mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 91 India mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 92 Japan mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 93 South Korea mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 94 Australia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 95 ROA mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 96 Latin America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 97 Latin America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 98 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 99 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 100 .Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 101 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 102 Latin America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%)
Table 103 Latin America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 104 Latin America mRNA Vaccines & Therapeutics market Forecast by End Users-2032 (US$ million, AGR%, CAGR %)
Table 105 Brazil mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 106 Argentina mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 107 Mexico mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 108 Rest of Latin America mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR %)
Table 109 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR%, CAGR %)
Table 110 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR%, CAGR %)
Table 111 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 112 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 113 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR%)
Table 114 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR%, CAGR %)
Table 115 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR%, CAGR%)
Table 116 Middle East & Africa mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR%, CAGR%)
Table 117 Middle East & Africa mRNA vaccines & therapeutics Market Forecast By End Users, 2022-2032 (US$ million, AGR%, CAGR%)
Table 118 Saudi Arabia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 119 UAE mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 120 Turkey mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 121 South Africa mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 122 Rest of Middle East mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR%, CAGR%)
Table 123 Key Business Strategies Adopted by Key Players in Global MRNA vaccines & therapeutics market
Table 124 AstraZeneca PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 AstraZeneca PLC: Pipeline Development
Table 126 AstraZeneca PLC : Strategic Outlook
Table 127 Moderna: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Moderna : mRNA Therapeutics & vaccines Pipeline 2022-2032
Table 129 Moderna : Strategic Outlook
Table 130 CureVac N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 CureVac N.V., Revenues from Contract Customers,2018-2021 (US$ million, AGR %)
Table 132 CureVac N.V.: mRNA Therapeutics & Vaccines Pipeline 2022-2032
Table 133 CureVac N.V.: Strategic Outlook
Table 134 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 135 BioNTech SE, Revenues from R&D Collaborations,2018-2021 (US$ million)
Table 136 BioNTech SE: mRNA Therapeutics & Vaccines Pipeline 2022-2032
Table 137 BioNTech SE: Strategic Outlook
Table 138 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 Pfizer Inc.: mRNA Vaccine Approval Status
Table 140 Pfizer Inc.: Strategic Outlook
Table 141 GSK Plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 142 GSK Plc: Revenues, By Segment, 2019-2021 (US$ million, AGR %)
Table 143 GSK Plc: Regional Revenues, 2018-2021 (US$ million)
Table 144 GSK Plc: mRNA Vaccine Approval Status
Table 145 GSK Plc: Strategic Outlook
Table 146 Arcturus Therapeutics Holdings Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 147 Arcturus Therapeutics Holdings Inc.: mRNA Vaccine and Therapeutics Pipeline
Table 148 Arcturus Therapeutics Holdings Inc.: Strategic Outlook
Table 149 Translate Bio ( A Sanofi Company).: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 150 Translate Bio ( A Sanofi Company).: mRNA Vaccine and Therapeutics Pipeline
Table 151 Translate Bio ( A Sanofi Company).: Strategic Outlook
Table 152 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 153 Sanofi: mRNA Vaccine and Therapeutics Pipeline
Table 154 Sanofi: Strategic Outlook
Table 155 eTheRNA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 156 ETheRNA: mRNA Strategic Collaborations
Table 157 ETheRNA: Strategic Outlook
Table 158 Stemirna Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 159 Stemirna Therapeutics: mRNA Strategic Collaborations
Table 160 Cartesian Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 161 Cartesian Therapeutics: mRNA Strategic Collaborations
Table 162 Cartesian : Strategic Outlook
Table 163 Ethris: mRNA Pipeline
Table 164 Ethris: Strategic Outlook

List of Figures
Figure 1 Global mRNA Vaccines & Therapeutics Market Segmentation
Figure 2 Global mRNA vaccines & therapeutics Market Forecast by Region: Market Attractiveness Index
Figure 3 Global mRNA vaccines & therapeutics Market by Therapeutics: Market Attractiveness Index
Figure 4 Global mRNA vaccines & therapeutics Market by Vector Platform: Market Attractiveness Index
Figure 5 Global mRNA vaccines & therapeutics Market by Delivery Platform: Market Attractiveness Index
Figure 6 Global mRNA vaccines & therapeutics Market by Route of Administration: Market Attractiveness Index
Figure 7 Global mRNA vaccines & therapeutics Market by Applications: Market Attractiveness Index
Figure 8 Global mRNA vaccines & therapeutics market by End Users : Market Attractiveness Index
Figure 9 Global mRNA vaccines & therapeutics market Dynamics
Figure 10 Global COVID Impact Analysis: mRNA vaccines & therapeutics Market Recovery Scenarios (US$ million, CAGR %)
Figure 11 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 12 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 13 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 14 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 15 Global mRNA vaccines & therapeutics Market: Porter’s Five Forces Analysis
Figure 16 Global mRNA vaccines & therapeutics Market: PEST Analysis
Figure 17 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Type
Figure 18 Global mRNA vaccines & therapeutics Market Forecast by Type, 2022-2032 (US$ million, AGR %)
Figure 19 Global mRNA vaccines & therapeutics Market Share Forecast by Type, 2022, 2032 (%)
Figure 20 Prophylactic vaccines Market Forecast by Region, 2022-2032 (US$ Mn)
Figure 21 Prophylactic vaccines Market Forecast by Region, 2022-2032 (%)
Figure 22 Therapeutic Vaccine Forecast by Region, 2022-2032 (US$ million)
Figure 23 Therapeutic Vaccine Forecast by Region, 2022-2032 (%)
Figure 24 mRNA Therapeutics Market Forecast by Region, 2022-2032 (US$ million)
Figure 25 mRNA Therapeutics Market Forecast by Region, 2022-2032 (%)
Figure 26 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Applications
Figure 27 Global mRNA vaccines & therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 28 mRNA vaccines & therapeutics Market Share Forecast by Applications, 2022, 2032 (%)
Figure 29 Cell Therapy Market Forecast by Region, 2022-2032 (US$ million)
Figure 30 Cell Therapy Market Share by Region, 2022-2032 (%)
Figure 31 mRNA Vaccine & Therapeutics, By Gene Editing Forecast by Region, 2022-2032 (US$ million)
Figure 32 mRNA Gene Editing Application Market, Forecast by Region, 2022-2032 (%)
Figure 33 mRNA Vaccine & Therapeutics, By Protein Replacement Forecast by Region, 2022-2032 (US$ million)
Figure 34 mRNA Protein Replacement Application Market, Forecast by Region, 2022-2032 (%)
Figure 35 mRNA Vaccine & Therapeutics, By Cancer Immunotherapy Forecast by Region, 2022-2032 (US$ million)
Figure 36 mRNA Cancer Immunotherapy Application Market, Forecast by Region, 2022-2032 (%)
Figure 37 mRNA Vaccine & Therapeutics, By Infectious Diseases Forecast by Region, 2022-2032 (US$ million)
Figure 38 mRNA Infectious Diseases Application Market, Forecast by Region, 2022-2032 (%)
Figure 39 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Vector Platform
Figure 40 Global mRNA vaccines & therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 41 Global mRNA vaccines & therapeutics Market Share Forecast by Vector Platform, 2022, 2032 (%)
Figure 42 Self-Amplifying mRNA Forecast by Region, 2022-2032 (US$ million)
Figure 43 Self-Amplifying mRNA Market, Forecast by Region, 2022-2032 (%)
Figure 44 Non-Amplifying mRNA Forecast by Region, 2022-2032 (US$ million)
Figure 45 Non-Amplifying mRNA Market, Forecast by Region, 2022-2032 (%)
Figure 46 Global mRNA Vaccines & Therapeutics Market: Growth Prospects by Delivery Platform
Figure 47 Global mRNA vaccines & therapeutics Market Forecast by Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 48 Global mRNA vaccines & therapeutics Market Share Forecast by Delivery Platform, 2022, 2032 (%)
Figure 49 Naked Delivery Platform Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 50 Naked Delivery Platform Market Forecast by Region, 2022-2032(%)
Figure 51 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ million)
Figure 52 Cell Specific Delivery Platform Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 53 Carrier Mediated Platform Market Forecast by Region, 2022-2032 (US$ million)
Figure 54 Carrier Mediated Delivery Platform Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 55 Viral Vector Market Forecast by Region, 2022-2032 (US$ million)
Figure 56 Viral Vector Market Share Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 57 Non-Viral Market Forecast by Region, 2022-2032 (US$ million)
Figure 58 Non-Viral Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 59 Lipid Nano-Particles Market Forecast by Region, 2022-2032 (US$ million)
Figure 60 Lipid Nano-Particles Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 61 Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ million)
Figure 62 Peptide-based Vectors Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 63 Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ million)
Figure 64 Polymer-based Vectors Market Forecast by Region, 2022-2032 (US$ million), 2022-2032 (%)
Figure 65 Global mRNA Vaccines & Therapeutics Market Forecast by Route of Administration 2022, 2027, 2032 (Revenue, CAGR %)
Figure 66 Global mRNA vaccines & therapeutics Market Forecast by Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 67 Global mRNA vaccines & therapeutics Market Share Forecast by Route of Delivery, 2022, 2032 (%)
Figure 68 Intradermal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 69 Intradermal Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 70 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 71 Subcutaneous Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 72 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 73 Intramuscular Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 74 Intravenous Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 75 Intravenous Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 76 Intranodal Route of Delivery Market Forecast by Region, 2022-2032 (US$ Mn, AGR%, CAGR %)
Figure 77 Global mRNA Intranodal Route of Delivery Market Forecast by Region, 2022-2032(%)
Figure 78 Global mRNA vaccines & therapeutics Market Forecast by End-Users 2022, 2027, 2032 (Revenue, CAGR %)
Figure 79 Global mRNA vaccines & therapeutics Market Forecast by End Users, 2022-2032 (US$ million, AGR %)
Figure 80 Global mRNA vaccines & therapeutics Market Share Forecast by End Users, 2022, 2032 (%)
Figure 81 Research Organizations Market Forecast by Region, 2022-2032 (US$ Mn )
Figure 82 Research Organizations Market Share Forecast, by Region, 2022-2032(%)
Figure 83 Hospitals & Clinics Market Forecast, by Region, 2022-2032 (US$ Mn )
Figure 84 Hospitals & Clinics Market Forecast, by Region, 2022-2032(%)
Figure 85 Global mRNA Vaccines & Therapeutics Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR%)
Figure 86 Global mRNA Vaccines & Therapeutics Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 87 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%))
Figure 88 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 89 Global mRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 90 Global MRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 91 Global MRNA vaccines & therapeutics market by Region, 2022-2032 (USD Mn, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 92 North America mRNA Vaccines & Therapeutics Market Attractiveness Index
Figure 93 North America mRNA Vaccines & Therapeutics market by Region, 2022, 2027 & 2032 (US$ million)
Figure 94 North America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 95 North America mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 96 North America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 97 North America mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 98 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 99 North America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 100 North America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 101 North America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 102 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 103 North America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 104 North America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 105 North America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 106 North America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 107 North America mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 108 North America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 109 North America mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 110 North America mRNA vaccines & therapeutics Market Forecast By End Users, 2022-2032 (US$ million, AGR %)
Figure 111 North America mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 112 U.S. mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 113 Canada mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 114 Europe mRNA Vaccines & Therapeutics Market Attractiveness Index,2022
Figure 115 Europe mRNA Vaccines & Therapeutics Market by Country, 2022, 2027 & 2032 (US$ million)
Figure 116 Europe mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 117 Europe mRNA vaccines & therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 118 Europe mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 119 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 120 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 121 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 122 Europe mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 123 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 124 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 125 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 126 Europe mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 127 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 128 Europe mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 129 Europe mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 130 Europe mRNA Vaccines & Therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 131 Europe mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 132 Europe mRNA Vaccines & Therapeutics Market Forecast by End Users-2032 (US$ million, AGR %)
Figure 133 Europe mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 134 Germany mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 135 UK mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 136 France mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 137 Spain mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 138 Italy mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 139 Rest of Europe mRNA Vaccines & Therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 140 Asia Pacific mRNA vaccines and Therapeutics Market Attractiveness Index
Figure 141 Asia Pacific mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million)
Figure 142 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 143 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 144 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 145 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 146 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 147 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 148 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 149 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 150 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 151 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 152 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 153 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 154 Asia Pacific mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 155 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 156 Asia Pacific mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 157 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 158 Asia Pacific mRNA vaccines & therapeutics market Forecast By End Users, 2022-2032 (US$ million, AGR %)
Figure 159 Asia Pacific mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 160 China mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 161 India mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 162 Japan mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 163 South Korea mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 164 Australia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 165 ROA mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 166 Latin America mRNA vaccines and Therapeutics Market Attractiveness Index
Figure 167 Latin America mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million)
Figure 168 Latin America mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 169 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 170 Latin America mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 171 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 172 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 173 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 174 Latin America mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 175 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 176 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 177 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 178 Latin America mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 179 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 180 Latin America mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 181 Latin America mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 182 Latin America mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 183 Latin America mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 184 Latin America mRNA Vaccines & Therapeutics Market Forecast by End Users, 2032 (US$ million, AGR %)
Figure 185 Latin America mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 186 Brazil mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 187 Argentina mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 188 Mexico mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 189 Rest of Latin America mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 190 Middle East & Africa mRNA vaccines and Therapeutics Market Attractiveness Index
Figure 191 Middle East & Africa mRNA Vaccine & Therapeutics Market, by Region, 2022, 2027 & 2032 (US$ million)
Figure 192 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Country, 2022-2032 (US$ million, AGR %)
Figure 193 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 194 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Types, 2022-2032 (US$ million, AGR %)
Figure 195 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Therapeutics, 2022 & 2032 (%)
Figure 196 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Platform, 2022-2032 (US$ million, AGR %)
Figure 197 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Vector Platform, 2022 & 2032 (%)
Figure 198 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 199 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Vector Delivery Platform, 2022 & 2032 (%)
Figure 200 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 201 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Vector Delivery Platform, 2022 & 2032 (%)
Figure 202 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Carrier Mediated Non-Viral Vector Delivery Platform, 2022-2032 (US$ million, AGR %)
Figure 203 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Carrier Mediated Non –Viral Vector Delivery Platform, 2022 & 2032 (%)
Figure 204 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by Applications, 2022-2032 (US$ million, AGR %)
Figure 205 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast by Applications, 2022 & 2032 (%)
Figure 206 Middle East & Africa mRNA vaccines & therapeutics market Forecast By Route of Delivery, 2022-2032 (US$ million, AGR %)
Figure 207 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast By Route of Delivery, 2022 & 2032 (%)
Figure 208 Middle East & Africa mRNA Vaccines & Therapeutics Market Forecast by End Users, 2032 (US$ million, AGR %)
Figure 209 Middle East & Africa mRNA Vaccines & Therapeutics Market Share Forecast By End Users, 2022 & 2032 (%)
Figure 210 Saudi Arabia mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 211 UAE mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 212 Turkey mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 213 South Africa mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 214 Rest of Middle East mRNA vaccines & therapeutics market Forecast, 2022-2032 (US$ million, AGR %)
Figure 215 Global mRNA vaccines & therapeutics market: Company Share Analysis, 2021
Figure 216 AstraZeneca PLC: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 217 AstraZeneca PLC Holdings AG: Core Operating Profit, 2017-2021 (US$ million, AGR%)
Figure 218 AstraZeneca PLC: R&D, 2017-2021 (US$ million, AGR%)
Figure 219 AstraZeneca PLC: Regional Pharmaceutical Revenues, By Region 2017-2021 (US$ million)
Figure 220 AstraZeneca PLC: Revenues, By Disease Area, 2021 (% share)
Figure 221 Moderna: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 222 Moderna, Revenues By Collaboration 2017-2021 (US$ million)
Figure 223 Moderna: R&D Expense, 2017-2021 (US$ million, AGR%)
Figure 224 Moderna: Regional Pharmaceutical Market Shares, 2021 (%)
Figure 225 CureVac N.V.: Net Revenue, 2018-2021 (US$ million, AGR %)
Figure 226 CureVac N.V.: R&D Expense, 2018-2021 (US$ million, AGR %)
Figure 227 CureVac N.V.: Regional Pharmaceutical Market Shares, 2018-2021 (%)
Figure 228 BioNTech SE: Net Revenue, 2018-2021 (US$ million, AGR %)
Figure 229 BioNTech SE: R&D Expense, 2018-2021 (US$ million, AGR %)
Figure 230 BioNTech SE: Regional Revenues by Collaborations, 2018-2021 (US$ million)
Figure 231 Pfizer Inc: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 232 Pfizer Inc. Net Income: 2017-2021 (US$ million, AGR %)
Figure 233 GSK Plc,: Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 234 GSK Plc. R&D Expense: 2017-2021 (US$ million, AGR %)
Figure 235 Arcturus Therapeutics Holdings Inc., Net Revenues=, 2019-2021 (US$ million, AGR %)
Figure 236 Arcturus Therapeutics Holdings Inc.: Collaboration Revenues, 2019-2021 (US$ million)
Figure 237 Translate Bio (A Sanofi Company), Net Revenues from Collaborations 2018-2020 (US$ million, AGR %)
Figure 238 Translate Bio ( A Sanofi Company).: R&D Expense, 2018-2020 (US$ million)
Figure 239 Sanofi, Net Revenue, 2017-2021 (US$ million, AGR %)
Figure 240 Sanofi: R&D Expense, 2017-2021 (US$ million)
Figure 241 Sanofi: Net Income, 2017-2021 (US$ million)
Figure 242 Sanofi: Business Segments Revenue, 2018-2021 (US$ million)

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（薬学的薬物）の最新刊レポート

皮膚科治療薬市場レポート：2024-2034

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（mRNA）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。